Real-world Characterization of Brazilian Patients with EGFR-mutated mNSCLC Treated with an EGFR/MET Bispecific Antibody.
Brazilian Journal of Oncology · 26.06.2026 · 22 (CP)
DOI: 10.1055/s-0046-1825232 ↗Kurz gefasst
Fachartikel in der Zeitschrift Brazilian Journal of Oncology, erschienen am 26.06.2026. Verfasst von Rafael Duarte Paes und 7 weiteren Autor:innen.
Abstract (Originalsprache)
All articles of this category (opens in new window) Address for correspondence Rafael Duarte Paes (r.dpaes@yahoo.com.br)
Introduction
Real-world data on patients with metastatic non-small cell lung cancer (mNSCLC) treated with amivantamab remain limited, particularly in Latin America. Understanding clinical characteristics, treatment patterns, and safety in routine practice is essential to optimize outcomes.
Objective
To describe the demographic, clinical, and therapeutic profile of patients with EGFR-mutated mNSCLC treated with amivantamab in a multicenter Brazilian cohort, including treatment duration, adverse events, and use of supportive care.
Methods
This retrospective study included patients with confirmed EGFR-mutated mNSCLC treated with amivantamab across multiple Brazilian cancer centers. Data was extracted from electronic medical records, including EGFR variant, treatment line, regimens, time to treatment discontinuation (TTD), time to first non-infusion-related adverse event, and use of supportive therapies. Descriptive statistics were applied.
Results
Data from 68 patients were analyzed. Median age was 64 years, with predominance of female patients (68%) and white individuals (54%). EGFR alterations included exon 19 deletions or L858R in 62% and exon 20 insertions in 24% and 14% with EGFR mutation uncommon/unknown. In both subgroups, most received amivantamab plus chemotherapy in second line or beyond (81%). Overall median TTD was 9.33 months (95% CI: 7.7–15.5). Adverse events occurred in 57%, mainly gastrointestinal and general disorders, with 16% grade 3–4. Supportive medications included dexamethasone (97%), antibiotic prophylaxis (41%), and oral anticoagulants (32%). Among patients with sensitizing EGFR mutations in second-line treatment, median TTD was 9.33 months (95% CI: 6.13–NA), consistent with previous data in this setting.
Conclusion
As one of the few real-world descriptions of bispecific antibody use for mNSCLC in Brazil, this study offers insights into treatment patterns, patient characteristics, and safety. While underreporting of adverse events was observed, it highlights opportunities to strengthen multidisciplinary involvement and adopt structured prophylaxis and toxicity monitoring. The treatment duration and supportive care practices suggest this therapeutic approach is a viable option in real-world oncology and may help guide quality improvement efforts. Publication History Article published online: 26 June 2026 © 2026. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution 4.0 International License, permitting copying and reproduction so long as the original work is given appropriate credit (https://creativecommons.org/licenses/by/4.0/) Thieme Revinter Publicações Ltda. Rua Rego Freitas, 175, loja 1, República, São Paulo, SP, CEP 01220-010, Brazil Bibliographical Record Rafael Duarte Paes, Christopher Lucas Negrete, Suzy Kaori Abe Shirassu, Mariana Perez Esteves Silva, Karen Priscila da Silva, Ariane Pereira Osorio, William Nassib William Junior, Rodrigo Dienstmann. Real-world Characterization of Brazilian Patients with EGFR-mutated mNSCLC Treated with an EGFR/MET Bispecific Antibody.. Brazilian Journal of Oncology 2026; 22. DOI: 10.1055/s-0046-1825232
Zitieren
APA
Paes, R. D., Negrete, C. L., Shirassu, S. K. A., Silva, M. P. E., Silva, K. P. D., Osorio, A. P., Junior, W. N. W., & Dienstmann, R. (2026). Real-world Characterization of Brazilian Patients with EGFR-mutated mNSCLC Treated with an EGFR/MET Bispecific Antibody. Brazilian Journal of Oncology, 22(CP). https://doi.org/10.1055/s-0046-1825232
Vancouver
Paes RD, Negrete CL, Shirassu SKA, Silva MPE, Silva KPD, Osorio AP, et al. Real-world Characterization of Brazilian Patients with EGFR-mutated mNSCLC Treated with an EGFR/MET Bispecific Antibody. Brazilian Journal of Oncology. 2026;22(CP). doi:10.1055/s-0046-1825232
BibTeX
@article{Paes2026,
author = {Paes, Rafael Duarte and Negrete, Christopher Lucas and Shirassu, Suzy Kaori Abe and Silva, Mariana Perez Esteves and Silva, Karen Priscila da and Osorio, Ariane Pereira and Junior, William Nassib William and Dienstmann, Rodrigo},
title = {Real-world Characterization of Brazilian Patients with EGFR-mutated mNSCLC Treated with an EGFR/MET Bispecific Antibody},
journal = {Brazilian Journal of Oncology},
year = {2026},
volume = {22},
number = {CP},
doi = {10.1055/s-0046-1825232}
}
EUVIMED